1197-04-2

Basic information

• Product Name: 6-HYDROXY-2-(1-METHYLETHYL)-4(3H)-PYRIMIDINONE
• Synonyms: 6-HYDROXY-2-(1-METHYLETHYL)-4(3H)-PYRIMIDINONE;6-hydroxy-2-isopropyl-3H-pyrimidin-4-one;6-hydroxy-2-propan-2-yl-3H-pyrimidin-4-one
• CAS NO: 1197-04-2
• Molecular Formula: C7H10N2O2
• Molecular Weight: 154.17
• Mol File: 1197-04-2.mol

Chemical Properties

• Melting Point: 296-297 °C (decomp)
• Appearance: /
• Density: 1.29±0.1 g/cm3(Predicted)
• PKA: 6.14±0.10(Predicted)
• CAS DataBase Reference: 6-HYDROXY-2-(1-METHYLETHYL)-4(3H)-PYRIMIDINONE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-HYDROXY-2-(1-METHYLETHYL)-4(3H)-PYRIMIDINONE(1197-04-2)
• EPA Substance Registry System: 6-HYDROXY-2-(1-METHYLETHYL)-4(3H)-PYRIMIDINONE(1197-04-2)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 1197-04-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-HYDROXY-2-(1-METHYLETHYL)-4(3H)-PYRIMIDINONE is used as a pharmaceutical intermediate for the production of various drugs. Its broad range of biological activities, including antifungal, antibacterial, antiviral, and anticancer properties, make it a valuable component in the development of new medications.
Used in Antifungal Applications:
6-HYDROXY-2-(1-METHYLETHYL)-4(3H)-PYRIMIDINONE is used as an antifungal agent to combat fungal infections. Its ability to inhibit fungal growth makes it a potential candidate for treating various fungal diseases.
Used in Antibacterial Applications:
6-HYDROXY-2-(1-METHYLETHYL)-4(3H)-PYRIMIDINONE is used as an antibacterial agent to fight against bacterial infections. Its effectiveness in inhibiting bacterial growth can be utilized in the development of new antibiotics to combat resistant strains.
Used in Antiviral Applications:
6-HYDROXY-2-(1-METHYLETHYL)-4(3H)-PYRIMIDINONE is used as an antiviral agent to prevent and treat viral infections. Its potential to inhibit viral replication and reduce viral load makes it a promising candidate for antiviral drug development.
Used in Anticancer Applications:
6-HYDROXY-2-(1-METHYLETHYL)-4(3H)-PYRIMIDINONE is used as an anticancer agent to target and inhibit the growth of cancer cells. Its potential to interfere with cancer cell proliferation and induce cell death makes it a valuable compound in the development of new cancer therapies.
Overall, 6-HYDROXY-2-(1-METHYLETHYL)-4(3H)-PYRIMIDINONE's diverse range of biological activities and potential as a pharmaceutical intermediate make it a valuable compound for various applications across different industries, particularly in the pharmaceutical sector.

Upstream product

• 22007-68-7 2-methylpropanimidamide hydrochloride 
• 108-59-8 malonic acid dimethyl ester 
• 108-13-4 malonodiamide 
• 97-62-1 Ethyl isobutyrate 
• 105-53-3 diethyl malonate 

Downstream Products

• 1850-98-2 4,6-dichloro-2-isopropylpyrimidine 
• 53039-34-2 2-isopropyl-5-nitro-1H-pyrimidine-4,6-dione 

Relevant articles and documents

'Green' synthesis of 2-substituted 6-hydroxy-[3H]-pyrimidin-4-ones and 4,6-dichloropyrimidines: Improved strategies and mechanistic study

An improved route to 2-substituted 6-hydroxy-[3H]-pyrimidin-4-ones 4 and to 2-substituted 4,6-dichloropyrimidines 5 is reported. Without using highly toxic reactants, compounds 4 can be prepared conveniently in a one pot synthesis on a one mol scale with average yields up to 80%. 4,6-Dichloropyrimidines 5, which are usually prepared in small quantities, are synthesized with average yields of 80%, using up to 80g of starting material. The mechanism of the chlorination of 4 is investigated computationally for the first time. The results suggest that the chlorination with phosphoryl chloride occurs in an alternating phosphorylation-chlorination manner (pathway 1) which is preferred over a sequence which starts with two phosphorylations. The investigated 4,6-dichloropyrimidines described herein form strong complexes with dichlorophosphoric acid but weak complexes with hydrochloric acid (generated during workup). These latter complexes explain the necessity of using aqueous sodium carbonate during the working up. In order to prevent possible formation of pyrimidinium salts between intermediates or the final dichloropyrimidines and unreacted hydroxypyrimidone, the latter could be deactivated with a strong acid such as dichlorophosphoric acid, thus allowing chlorination but prohibiting salt formation. Because of its general applicability to all nitrogen heterocycle chlorinations with phosphoryl chloride, the proposed route to dichloropyrimidines without solvent or side products, using less toxic reactants, is of general synthetic interest.

Compounds as syk kinase inhibitors

The present invention relates to a compound of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by inhibition of Syk kinase.

FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF

The present invention provides a fused heterocycle derivative having a strong Smo inhibitory activity, and use thereof. Specially, the present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or salt thereof, and a medicament containing the compound or a prodrug thereof, which is an Smo inhibitor or an agent for the prophylaxis or treatment of cancer.

Discovery of a potent nicotinic acid receptor agonist for the treatment of dyslipidemia

Nicotinic acid has been used clinically for decades to control serum lipoproteins. Nicotinic acid lowers very low-density lipoprotein (VLDL)-cholesterol, low-density lipoprotein (LDL)-cholesterol, and lipoprotein-a (LPa), and it is also effective in raising high-density lipoprotein (HDL)-cholesterol. However, nicotinic acid has several side effects in clinical use. The most notable is intense cutaneous vasodilation "flushing"+ on the upper body and face. We discovered a pyranopyrimidinedione series to be nicotinic acid receptor agonists. A potent nicotinic acid receptor agonist from this series {5-(3-cyclopropylpropyl)-2-(difluoromethyl)-3H-pyrano[2,3-d] pyrimidine-4,7-dione}with reduced flushing side effect in dogs was identified.

4-AMINO-PYRIMIDINE DERIVATIVES

4-Amino-pyrimidine derivatives of Formula (I), wherein the meaning of the different substituents are those indicated in the description. These compounds are useful as histamine H4 receptor antagonists.

PIPERIDINE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS

A novel piperidine derivative represented by the formula (I) (I) wherein Ar is a phenyl group optionally having substituent(s), R?1? is a hydrogen atom, a hydrocarbon group optionally having substituent(s), an acyl group or a heterocyclic group optionally having substituent(s), Z is a methylene group optionally having C?1-6#191 alkyl group(s), ring A is a piperidine ring optionally further having substituent(s), and B is a monocyclic aromatic heterocyclic group optionally having substituent(s) (substituents of monocyclic aromatic heterocycle may be bonded to each other to form a ring), or a salt thereof has a superior tachykinin receptor antagonistic action and the like, and is useful as an agent for the prophylaxis or treatment of lower urinary tract disease and the like.